CCR2 and type 2 diabetes mellitus: A previous randomized trial involving patients with type 2 diabetes reported that administration of a CCR2 antagonist, JNJ‐41443532, resulted in decreased levels of weighted‐mean and fasting plasma glucose over 28 days of treatment.30